Skip to main content

Trastuzumab and Hyaluronidase-oysk

Placeholder slot
 (tras-TOO-zoo-mab … HY-al-yoo-RAH-nih-days)

This page contains brief information about trastuzumab and hyaluronidase-oysk and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Herceptin Hylecta
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Trastuzumab and hyaluronidase-oysk is approved to treat:

Trastuzumab and hyaluronidase-oysk is a form of trastuzumab that is given as a subcutaneous injection. This form can be given more quickly than trastuzumab, which is given as an infusion. This shortens the amount of time it takes to receive each treatment. For more information about trastuzumab that may apply to trastuzumab and hyaluronidase-oysk, see the Drug Information Summary for Trastuzumab.

More About Trastuzumab and Hyaluronidase-oysk

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Cancer Therapies

Biological Therapies for Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Trastuzumab And Hyaluronidase-oysk - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: